Opioid Prescribing and the Ethical Duty to Do No Harm
- 1 May 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in American Journal of Law & Medicine
- Vol. 46 (2-3), 297-310
- https://doi.org/10.1177/0098858820933500
Abstract
Doctors have two ethical duties: to cure disease or ease suffering and, also, to do no harm. The ethical duty to “Do No Harm” has been used to justify two sides of a pendulum swing in the philosophy of opioid prescribing for pain. In the 1990s, it was invoked to expand prescribing, and more recently to justify dramatic reductions in prescription opioid use. In this Article, we explore whether prescribing opioids for pain presents challenges that differ from the ordinary mandate physicians face as they balance the call for action with the imperative to do no harm [DNH]. We argue that the treatment of pain differs in three important ways. First, the fact that pain is present and occurrent reduces uncertainty about the need for action, and thus strengthens the reasons to act. Second, while DNH applies to both physicians and policymakers, each has distinct duties: physicians have a duty to the individual patient; policymakers have a duty to society. As a result, harm from drug diversion should weigh little when clinicians decide how to treat individual patients. Public health officials, by contrast, rightly consider societal effects. However, in doing so, they must adopt policies that mitigate the ethical burdens placed on physicians, respect the testimony of patients in pain, and pay particular attention to how policy guidance is likely to be implemented by others. Finally, we address what duties are owed to patients who are currently taking opioid medication, given evidence that they are experiencing significant barriers in receiving healthcare. We argue that once treatment has been initiated, there are special duties to these patients.Keywords
This publication has 21 references indexed in Scilit:
- Durations of Opioid, Nonopioid Drug, and Behavioral Clinical Trials for Chronic Pain: Adequate or Inadequate?Pain Medicine, 2016
- Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whitesProceedings of the National Academy of Sciences of the United States of America, 2016
- Opioid Abuse in Chronic Pain — Misconceptions and Mitigation StrategiesThe New England Journal of Medicine, 2016
- CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016MMWR. Recommendations and Reports, 2016
- Opioids for Chronic Pain: First Do No HarmAnnals of Family Medicine, 2012
- Long-term opioid management for chronic noncancer painEmergencias, 2010
- Opioids and the treatment of chronic pain: Controversies, current status, and future directions.Experimental and Clinical Psychopharmacology, 2008
- Prevalence and characteristics of opioid use in the US adult populationPain, 2008
- Pharmaceutical Company Payments to PhysiciansJAMA, 2007
- The Company We Keep: Why Physicians Should Refuse to See Pharmaceutical RepresentativesAnnals of Family Medicine, 2005